共 499 条
[1]
Jones PW(2005)St. George’s Respiratory questionnaire: MCID COPD 2 75-79
[2]
Witek TJ(2003)Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 21 267-272
[3]
Mahler DA(2011)Blinded 12- week comparison of once-daily indacaterol and tiotropium in COPD Eur Respir J 38 797-803
[4]
Buhl R(2010)L Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 473-479
[5]
Dunn LJ(2010)Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 155-162
[6]
Disdier C(2011)Efficacy and safety of once-daily NVA237 in patients with moderate to severe COPD: the GLOW1 trial Respir Res 12 156-9
[7]
Lassen C(2010)Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study BMC Pulm Med 10 1-1984
[8]
Amos C(2011)Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies Clin Ther 33 1974-1114
[9]
Henley M(2012)Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study Eur Respir J 40 1106-389
[10]
Kramer B(2012)Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study Respirology 17 379-726